

Lupin to Reorganise Sale Structure for Suprax[®]

BSE : 500257	NSE: LUPIN	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
---------------------	-------------------	-------------------------	--------------------------

Mumbai, 21 February 2006: Lupin Ltd. reported that owing to the encouraging trend seen in the sales of its Suprax[®] brand in the US market, Lupin Pharmaceutical Inc (LPI); a wholly owned subsidiary of the Company, is reorganizing its sales structure.

The sales force currently contracted through Ventiv Health US Sales LLC will be internalized at the beginning of the next quarter. As a part of this reorganization process, LPI will further focus on the high potential Suprax[®] prescribers in the non-pediatric segment as well. Accordingly LPI has decided to discontinue its co-promotion agreement with Cornerstone BioPharma Inc.

About Lupin

Headquartered in Mumbai, Lupin (<http://www.lupinworld.com>) develops, manufactures and markets generic intermediates, active pharmaceutical ingredients and finished dosages. Its FY 2004-05 revenues were Rs.12 billion. 11 of Lupin's plant have been approved by the USFDA and two facilities have been approved by the UKMHRA

For further information contact:

Raju Kane

The Source

Tel. +91 22 27564822, 27566683

Telefax : +91 22 27576555

Mobile : +91 98200 45656

E-mail: rajukane@sourcepr.com